Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to new therapies.
About half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators.
Researchers have used a cutting-edge model system to uncover the mechanism by which SARS-CoV-2 induces new cases of diabetes and worsens complications in people who already have it.
A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to accelerate the development of better treatment regimens for tuberculosis.
Study opens the door to exploring new targets for therapies for fibrolamellar carcinoma, which does not respond to conventional treatments and leaves patients with approximately a year to live on average once it is detected.
The study paves the way for using the novel manufacturing process and quality controls to move cell therapy production further along toward applying it in a clinic.
A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.
Research at Weill Cornell Medicine suggests that childhood immunization against HIV could one day provide protection before risk of contracting the potentially fatal infection dramatically increases in adolescence.
The study shows that artificial intelligence and machine learning technologies can effectively and efficiently subtype pathology samples from patients with rheumatoid arthritis.